Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.42 |
| ▸ | RAB9A | P51151 | 7/20 | 0.42 |
| ▸ | STK4 | Q13043 | 1/20 | 0.40 |
| ▸ | STK3 | Q13188 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.38 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.38 |
| ▸ | MTOR | P42345 | 2/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3753112 | 0.93 | ACVR1 (0.39) | NPC1RAB9ASTK4STK3LRRK2 | |
| SCHEMBL3740333 | 0.91 | AURKA (0.39) | NPC1RAB9A | |
| SCHEMBL3750781 | 0.88 | SYK (0.42) | NPC1RAB9ACNR2KDM4EPIK3CD | |
| SCHEMBL12956198 | 0.88 | CNR2 (0.53) | NPC1RAB9ASTK4STK3CNR2 | |
| SCHEMBL1038537 | 0.81 | BTK (0.56) | NPC1RAB9A | |
| SCHEMBL3963743 | 0.81 | BTK (0.54) | RAB9AKDM4E | |
| SCHEMBL3753118 | 0.81 | CDK4 (0.37) | NPC1RAB9ACNR2KDM4ESYK | |
| SCHEMBL1038028 | 0.80 | BTK (0.49) | NPC1RAB9A | |
| SCHEMBL1041076 | 0.79 | BTK (0.50) | RAF1BRAF | |
| SCHEMBL1042485 | 0.79 | BTK (0.43) | NPC1RAB9APIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838523-B2 | Certain substituted amides, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. (US) | 2010-11-23 | — | — | US | disclosed |
| EP-2079726-A2 | SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI Pharmaceuticals, Inc. (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20080153834-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | GILEAD CONNECTICUT, INC. | 2008-06-26 | — | — | US | disclosed |
| WO-2008033857-A2 | SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153834-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | BTK, SYK, MYD88 | NPC1 1118/4885RAB9A 2778/4885STK4 2659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.